Search
Thiotepa
go.drugbank.com/drugs/DB04572ApprovedInvestigationalN,N'N'-triethylenethiophosphoramide (ThioTEPA) is a cancer chemotherapeutic member of the alkylating agent group, now in use for over 50 years. … It is mostly used to treat breast cancer, ovarian cancer and bladder cancer. It is also used as conditioning for Bone marrow transplantation. Its main toxicity is myelosuppression.
Panobinostat
go.drugbank.com/drugs/DB06603ApprovedInvestigationalPanobinostat is an oral deacetylace (DAC) inhibitor approved on February 23, 2015 by the FDA for the treatment of multiple myeloma. … The approval was accelerated based on progression-free survival, therefore confirmatory trials by the sponsor to demonstrate clinical efficacy in multiple myeloma treatment are in progress of being conducted
Synonyms: (2E)-N-hydroxy-3-[4-({[2-(2-methyl-1H-indol-3-yl)ethyl]amino}methyl)phenyl]acrylamide, 2-PROPENAMIDE, N-HYDROXY-3-(4-(((2-(2-METHYL-1H-INDOL-3-YL)ETHYL)AMINO)METHYL)PHENYL)-, (2E)-Mirabegron
go.drugbank.com/drugs/DB08893ApprovedInvestigationalMirabegron is a sympathomimetic beta-3 adrenergic receptor agonist used to relax the smooth muscle of the bladder in the treatment of urinary frequency and incontinence. … Mirabegron has a comparatively favorable adverse effect profile as compared to other available treatment options, and its complementary mechanism to the antimuscarinics that came before it allows for its
Categories: Adrenergic beta-3 Receptor AgonistsProducts: MYRBETRIC® 50 MG TABLETAS DE LIBERACION PROLONGADA, MYRBETRIC® 25 MG TABLETAS DE LIBERACION PROLONGADADengue virus serotype 1
go.drugbank.com/drugs/DB22664ApprovedDengue virus serotype 1 is a serotype of _Orthoflavivirus denguei_ known to cause dengue fever. … [L53368] Qdenga was approved for use in the European Union in December 2022.[L53373]
Zongertinib
go.drugbank.com/drugs/DB18762ApprovedInvestigational[L53873,A274363] It covalently binds to the HER2 receptor, including exon 20 insertions, and inhibits downstream signaling pathways while sparing wild-type epidermal growth factor receptor (EGFR), which … serves to limit associated toxicities.
Categories: Human epidermal growth factor receptor 2 (HER2) tyrosine kinase inhibitorsNadofaragene firadenovec
go.drugbank.com/drugs/DB17381ApprovedInvestigationalIt is the first gene therapy approved by the FDA for the treatment of bladder cancer.[L44381,L44431] BCG-unresponsive NMIBC has a high recurrence and is notably difficult to treat. … The use of nadofaragene firadenovec provides a therapeutic alternative to patients seeking non-surgical alternatives for the treatment of BCG-unresponsive NMIBC.
Synonyms: TR-002, Replication-deficient adenovirus type 5 (ad5) vector encoding the human interferon alpha 2 (ifna2, interferon alpha-2b) gene under the control of the cytomegalovirus (cmv) immediate-early enhancer/promoterFusarium oxysporum
go.drugbank.com/drugs/DB10806ApprovedFusarium oxysporum allergenic extract is used in allergenic testing.
Mixtures: Number Ten Mold Mixture, Number Ten Mold MixtureLapatinib
go.drugbank.com/drugs/DB01259ApprovedInvestigationalIt binds to the intracellular phosphorylation domain to prevent receptor autophosphorylation upon ligand binding. … It was approved by the FDA on March 13, 2007, for use in patients with advanced metastatic breast cancer in conjunction with the chemotherapy drug capecitabine.
Categories: Human epidermal growth factor receptor 2 (HER2) tyrosine kinase inhibitorsNimesulide
go.drugbank.com/drugs/DB04743ApprovedWithdrawnDue to concerns about the risk of hepatotoxicity, nimesulide has been withdrawn from market in many countries. … Its approved indications are the treatment of acute pain, the symptomatic treatment of osteoarthritis and primary dysmenorrhoea in adolescents and adults above 12 years old.
Products: FLAMOZIN TTolfenamic acid
go.drugbank.com/drugs/DB09216ApprovedIt is used in the UK as a treatment for migraine under the name of Clotam.[L1292] In the US, it presents a Status class I by the FDA. … By the European Medicine Agency, it was granted in 2016 with the status of orphan for the treatment of supranuclear palsy.[L1291]